FDA Approves Weight-Loss Drug Zepbound for Sleep Apnea Treatment [k3UEtJHgSb4]

FDA Approves Weight-Loss Drug Zepbound for Sleep Apnea Treatment [k3UEtJHgSb4]

| 1h 28m 28s | Video has closed captioning.

"FDA Approves Weight-Loss Drug Zepbound for Sleep Apnea Treatment" The FDA has approved Zepbound, a groundbreaking prescription drug for managing obstructive sleep apnea in patients with obesity. This is the first FDA-approved medication targeting this condition. 📌 Key Highlights: Condition Treated: Obstructive Sleep Apnea (OSA) Drug Class: GLP-1 Receptor Agonists Benefits: Reduced apnea episodes, significant weight loss (18–20%), improved cardiovascular health Trial Results: Average weight loss of 45–50 pounds over a year Cost: $1,060/month (discounts available) Discover how this new treatment offers hope to millions battling OSA and obesity. 🔔 Like, share, and subscribe for more health and wellness updates! #FDAApproval #Zepbound #SleepApneaTreatment #WeightLossDrug #ObstructiveSleepApnea #HealthNews #ObesityTreatment #GLP1Drugs #MedicalBreakthrough #diet pills research #medical weight loss of ny